Published in Medical Letter on the CDC and FDA, March 13th, 2005
Macugen was approved by the U.S. Food and Drug Administration on December 17, 2004 for use in the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.
Eyetech and Pfizer launched Macugen on January 20, 2005.
Eyetech is a biopharmaceutical company that specializes in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA